Novel thiazole HSD17B13 inhibitor, preparation method thereof and application of novel thiazole HSD17B13 inhibitor as medicine

By developing new methylthiazole HSD17B13 inhibitors, the problem that the existing technology is difficult to effectively prevent and treat non-alcoholic fatty liver and diabetes is solved, effective inhibition of HSD17B13 and targeted liver distribution are achieved, and fatty acid metabolism is significantly improved. Liver health.

CN118955491APending Publication Date: 2024-11-15GUANGDONG PHARMA UNIV
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411240160.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing treatments are difficult to effectively prevent and treat non-alcoholic fatty liver, diabetes and other related metabolic syndromes, especially the role of HSD17B13 in these diseases is not fully utilized.

Method used

A novel methylthiazole HSD17B13 inhibitor has been developed, with excellent HSD17B13 inhibitory activity and long-lasting liver targeted distribution characteristics, and is used to treat hyperlipidemia, non-alcoholic fatty liver, drug-induced liver injury, hepatocellular carcinoma etc.

Benefits of technology

The HSD17B13 inhibitor significantly reduced the lipotoxic effect in the liver, improved fatty acid metabolism, had potential drug development prospects for the treatment and prevention of diabetes, hyperlipidemia and fatty liver, and showed safety and efficacy in animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955491A_ABST
    Figure CN118955491A_ABST
Patent Text Reader

Abstract

The invention relates to an effective amount of novel methylthiazole derivative as shown in a general formula (I), a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of drugs for treating HSD17B13 related diseases, and compared with the prior art, the compound has a wider application prospect. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a novel methylthiazole derivative, a preparation method and application thereof, and belongs to the field of pharmaceutical chemistry. The structure of the derivative of the present invention is unique and novel in the field. Background Art

[0002] The prevalence of obesity, metabolic syndrome, and type 2 diabetes continues to rise worldwide, with a corresponding increase in the prevalence of associated complications and comorbidities, including cardiovascular disease, renal disease, and nonalcoholic fatty liver disease (MAFLD). Among them, nonalcoholic steatohepatitis (MASH) and cirrhosis increase the clinical and economic resource burden. The progression of nonalcoholic fatty liver disease initially manifests as the accumulation of neutral lipids in the liver, with the development of severe liver inflammation and fibrosis, eventually forming hepatocellular carcinoma (HCC) and ultimately loss of liver function (end-stage liver disease, ESLD).

[0003] The liver is a central regulator of lipid balance. As a key organ for lipid homeostasis, hepatocytes mobilize lipids to meet the body's energy needs and store excess lipids in lipid droplets. HSD17B13 belongs to the 17β-hydroxysteroid dehydrogenase (17B-HSDS) family and regulates steroid hormone receptors in target tissues. Most members of this family act on sex hormone metabolism, while a small number of other members play a key role in cholesterol biosynthesis and fatty acid elongation and oxidation. HSD17B13 is a liver-specific lipid droplet-associated protein with very low levels in organs such as the gastrointestinal spleen, muscle, and urinary system. Its enzymatic cleavage pathway involves steroids, proinflammatory lipid mediators, and retinol.

[0004] Genome-wide association studies of histological features of non-alcoholic fatty liver disease and steatohepatitis have shown that HSD17B13 is upregulated in the liver of MAFLD patients. Another study also showed that several inactivating variants of the HSD17B13 gene were associated with a reduced risk of chronic liver diseases (including MAFLD), and may have a protective effect on the progression of non-alcoholic fatty liver disease from simple steatosis to MASH, liver fibrosis, cirrhosis and hepatocellular carcinoma. Expression profiling studies in mice have shown that HSD17B13 is highly expressed in the liver and is closely related to a high-fat diet. Preclinical experiments have found that AAV-mediated overexpression of HSD17B13 promotes lipid accumulation in the liver of mice, indicating that HSD17B13 is closely related to fatty acid metabolism. Compared with the control group, HFD-fed mice that specifically reduced HSD17B13 expression had significantly lower serum ALT and liver TG levels.

[0005] Currently, the treatment under clinical investigation is to silence HSD17B13 by administering siRNA (NCT04202354), mimicking the phenotype of individuals lacking this protein, thereby improving fatty liver. The latest data from mechanistic studies and preclinical studies conducted by small molecule drugs show that inhibiting the activity of HSD17B13 can prevent the deterioration of non-alcoholic fatty liver disease. HSD17B13 targets lipid droplets, and the protease activity depends on the lipid droplet target and the enzyme substrate factor (NAD + ) binding site. B1-3231 is an HSD17B13 enzyme inhibitor that reduces palmitic acid-induced lipotoxicity in mouse and human hepatocytes.

[0006]

[0007] The present invention relates to a novel HSD17B13 inhibitor, which has excellent HSD17B13 inhibitory activity and in vivo glucose-lowering and lipid-regulating activity, and has a persistent liver-targeted distribution characteristic. Therefore, the HSD17B13 inhibitor and its pharmaceutically acceptable salt can be potentially used to treat or prevent metabolic syndromes related to diabetes, hyperlipidemia and fatty liver, and has broad prospects for drug development. Summary of the invention

[0008] The technical problem to be solved by the present invention is to provide for the first time a method for preparing a novel methylthiazole HSD17B13 inhibitor, thereby providing the possibility for the application of HSD17B13 inhibitors in the diagnosis, treatment and prevention of hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, drug-induced liver injury, hepatocellular carcinoma, acute kidney injury, diabetes and other related diseases.

[0009] The methylthiazole HSD17B13 inhibitor of the present invention comprises an effective amount of a compound represented by the general formula (I):

[0010]

[0011] in,

[0012] R1 is selected from any of the following structures:

[0013]

[0014] R2 is selected from any of the following structures:

[0015] Wherein, R3 is selected from one or more hydrogen, halogen, alkyl, hydroxyl, alkoxy, R4 and R5 are each independently selected from hydrogen, alkyl, cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl is optionally further substituted by one or more groups selected from halogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl.

[0016] Preferred compounds have the general formula (I) or their pharmaceutically acceptable salts:

[0017] R1 is selected from any of the following structures:

[0018]

[0019] R2 is selected from any of the following structures:

[0020] Wherein, R3 is selected from one or more of hydrogen, halogen, C 1- C 10 Alkyl, hydroxyl, C 1- C6 alkoxy, R4 and R5 are each independently selected from hydrogen, C 1- C 10 Alkyl, C3-C6 cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl, aryl, heteroaryl.

[0021] More preferred compounds of the present invention include, but are not limited to:

[0022] (2-(3,5-difluoro-4-hydroxyphenyl)-4-methylthiazol-5-yl)((2R,6S)-2,6-dimethylmorpholinyl)methanone (1)

[0023] (2-(3,5-dichloro-4-hydroxyphenyl)-4-methylthiazol-5-yl)((2R,6S)-2,6-dimethylmorpholinyl)methanone (2)

[0024] ((2R,6S)-2,6-dimethylmorpholinyl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (3)

[0025] (4-Methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(morpholinyl)methanone (4)

[0026] (4-Hydroxypiperidin-1-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (5)

[0027] (8-Oxo-3-azabicyclo[3.2.1]octan-3-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (6)

[0028] ((1R, 3R, 5S)-3-Hydroxy-8-azabicyclo[3.2.1]octan-8-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (7)

[0029] (4-Methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(4-methylpiperazin-1-yl)methanone (8)

[0030] 1-(4-(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carbonyl)piperazin-1-yl)ethan-1-one (9)

[0031] 1-(4-Methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carbonyl)piperidine-4-carboxylic acid methyl ester (10)

[0032] Isoindolin-2-yl(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone(11)

[0033] (3,4-Dihydroisoquinolin-2(1H)-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (12)

[0034] (4-Methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(4-phenylpiperidin-1-yl)methanone (13)

[0035] 4-Methyl-N-(p-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (14)

[0036] 4-Methyl-N-(m-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (15)

[0037] N-(2-Chlorophenyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (16)

[0038] N-Benzyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (17)

[0039] N-(4-Chlorobenzyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (18)

[0040] 4-Methyl-N-(1-phenylethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (19)

[0041] N-(Cyclopropyl(phenyl)methyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (20)

[0042] N-Benzyl-N,4-dimethyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (21)

[0043] N-Benzyl-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (22)

[0044] N-Benzyl-N-cyclopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (23)

[0045] N-Benzyl-4-methyl-N-phenyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (24)

[0046] N, N-dibenzyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (25)

[0047] N-Benzyl-4-methyl-N-(1-phenylethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (26)

[0048] N-isopropyl-4-methyl-N-(2-methylbenzyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (27)

[0049] N-isopropyl-4-methyl-N-(4-methylbenzyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (28)

[0050] N-(4-Fluorobenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (29)

[0051] N-(4-Chlorobenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (30)

[0052] N-(3,4-Dichlorophenyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (31)

[0053] N-(4-chloro-2-methylbenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (32)

[0054] N-(4-Hydroxy-3,5-dimethylbenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (33)

[0055] N-isopropyl-4-methyl-N-(thiophen-2-ylmethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (34)

[0056] N-isopropyl-4-methyl-N-(thiazol-4-ylmethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (35)

[0057] N-(Benzothiophen-2-ylmethyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (36)

[0058] N-(Benzofuran-2-ylmethyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (37)

[0059] N-Benzyl-4-methyl-N-(p-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (38)

[0060] N-(4-Chlorobenzyl)-N-isobutyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (39)

[0061] N-(4-Chlorobenzyl)-4-methyl-N-(3-phenylpropyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (40)

[0062] N-(4-Chlorobenzyl)-4-methyl-N-phenethyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (41)

[0063] N-(4-Chlorobenzyl)-4-methyl-N-(4-methylphenethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (42)

[0064] Another aspect of the present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of the compound or a pharmaceutically acceptable salt thereof and a suitable carrier, diluent or excipient.

[0065] The invention relates to use of the compound or a pharmaceutically acceptable salt thereof in preparing a drug for treating HSD17B13-mediated diseases.

[0066] The present invention also relates to the use of the compound or its pharmaceutical composition in the preparation of a drug for preventing and / or treating at least one of primary biliary cirrhosis, nonalcoholic steatohepatitis, alcoholic steatohepatitis, hyperlipidemia, obesity, atherosclerosis, organ fibrosis, cirrhosis, diabetes and its complications, acute kidney injury, and inflammatory diseases.

[0067] Detailed description of the invention

[0068] Unless otherwise stated, the following terms used in the specification and claims have the following meanings.

[0069] Any general formula or structure shown herein, including compounds of general formula (1), is also intended to represent unlabeled and isotopically labeled forms of the compounds. Isotope-labeled compounds have the structure shown in the molecular formula given herein, except that one or more atoms are replaced by atoms with a selected atomic mass or mass number. Examples of isotopes that may be included in the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, and in the compounds of the present invention, any atom that is not explicitly indicated as a specific isotope is intended to represent any stable isotope of the atom. Unless otherwise stated, when a position is explicitly indicated with "H" or "hydrogen", it should be understood that the position is hydrogen of its isotopic composition. Therefore, in the compounds of the present invention, any atom explicitly indicated as deuterium (D) is intended to represent deuterium.

[0070] "Pharmaceutical composition" means a mixture containing one or more compounds of the present invention and other chemical components, such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to promote the absorption of the active ingredient by the organism and facilitate the active ingredient to exert its biological activity in the organism. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1 : Distribution curve of oral compound 30 (20 mg / kg) in the blood and liver of mice.

[0072] Figure 2 :Effects of compound 30 (20 mg / kg / d) on DIO mice. (A) Experimental procedure of DIO model. (B) OGTT experiment with oral administration of 3 g / kg glucose: Time-dependent changes in blood glucose levels. (B') represents the AUC shown in (B) 0-90min Blood glucose level. (C) Serum ALT level; (D) Serum AST level; (E) Serum ALP level; (F) Serum TBA level; (G) Serum TBIL level; (H) Serum UA level. All values ​​are expressed as mean ± standard deviation (n = 6), and the comparison between the two groups is * P<0.05, ** P < 0.01 and *** P<0.001 indicated a significant difference.

[0073] Figure 3:Effects of compound 30 on histological characteristics of DIO mice. (A) HE staining of liver sections, magnified 200 times. Scale bar: 100 μm. (B) Liver weight ratio; (C) Fatty degeneration score; (D) Serum LDL level; (E) Serum TC level; (F) Serum TG level; (G) Liver TC level; (H) Liver TG level; (I) Liver TNF-α level; (J) Liver IL-1β level; (K) Liver MCP-1 level: (L) Liver IL-6 level. All values ​​are expressed as mean ± SD (n = 6), compared between the two groups, * P<0.05, ** P < 0.01 and *** P<0.001 indicated a significant difference.

[0074] Figure 4 :In vivo anti-NASH activity study of compound 30. (A) HE staining and Masson staining of liver sections, magnified 200 times. Scale bar: 100 μm. (B) Liver weight; (C) Liver weight ratio; NAS score of HE staining of liver sections: (D) fatty degeneration score; (E) ballooning degeneration score; (F) inflammation score; (G) NAS total score; (H) Masson staining area statistics of liver sections. All values ​​are expressed as mean ± SD (n = 6), compared between the two groups, * P<0.05, ** P < 0.01 and *** P<0.001 indicated a significant difference. DETAILED DESCRIPTION

[0075] The present invention will be further described below in conjunction with the examples. It should be noted that the following examples are only for illustration, and are not intended to limit the present invention. Various changes made by those skilled in the art based on the teachings of the present invention should be within the scope of protection of the claims of this application.

[0076] Synthesis and preparation of the compounds of the present invention:

[0077] Synthetic route 1:

[0078]

[0079]

[0080] Reagents and conditions: (a) oxalyl chloride, dimethylformamide, dichloromethane, 0℃, 3h; (b) aqueous ammonia, 0℃, 1h; (c) Lawesson's reagent, anhydrous tetrahydrofuran, 70℃, 5h; (d) ethyl 2-chloroacetoacetate, anhydrous ethanol, 70℃, overnight; (e) lithium hydroxide monohydrate, tetrahydrofuran / methanol / water, room temperature, 3h; (f) 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, dichloromethane, room temperature, overnight; (g) boron tribromide, dichloromethane, 0℃, overnight.

[0081] 3,5-Difluoro-4-methoxybenzoic acid (1.0 equiv) was dissolved in anhydrous dichloromethane (10 mL), oxalyl chloride (3 equiv) was slowly added dropwise, and then 2-3 drops of N,N-dimethylamide (0.1 equiv) were added dropwise to catalyze. The reaction was carried out at room temperature for 3 hours. After the plate was plated and the reaction was confirmed to be complete, the solvent was distilled off under reduced pressure, dichloromethane was added, and distillation was carried out under reduced pressure. The operation was repeated for more than 3 times to completely remove the residual oxalyl chloride as much as possible, and the chlorinated crude product was obtained for use. Under ice bath conditions, the dichloromethane solution of the above crude product was added dropwise to ammonia water (10 ml). After the addition was complete, the ice bath was removed and the reaction was carried out at room temperature for 1 hour. After the reaction was completed, the solvent was evaporated under reduced pressure, water (10 mL) was added to dilute, the pH was adjusted to be weakly alkaline, and extracted with ethyl acetate (20 mL×3). The organic phases were combined and washed with saturated brine (20 mL×3), and dried over anhydrous sodium sulfate to obtain 1a. 1a (1 equiv) was dissolved in anhydrous tetrahydrofuran, and Lawesson's reagent (1.1 equiv) was added to react at 70°C overnight. After the reaction was complete by thin layer chromatography, saturated sodium bicarbonate solution was added to quench the reaction, the solvent was evaporated under reduced pressure, water (10 mL) was added to dilute, the pH was adjusted to be weakly alkaline, and ethyl acetate (20 mL×3) was used for extraction. 2a was purified by column chromatography. 2a (1 equiv) and ethyl 2-chloroacetoacetate (6 equiv) were dissolved in anhydrous ethanol, reacted at 70°C overnight. After the reaction was complete by thin layer chromatography, the temperature was lowered to stand to precipitate crystals, and intermediate 3a was obtained by suction filtration. 3a (1 equiv) was dissolved in a mixed solvent (10 mL) of tetrahydrofuran / methanol / water (3:3:1), and lithium hydroxide monohydrate (1.5 equiv) was added. The reaction was carried out at room temperature for 4 h, the solvent was dried by spin drying, dilute hydrochloric acid was added dropwise, the pH was adjusted to 3-4 to precipitate a white solid, and the solid was suction filtered to dry to obtain intermediate 4a. 4a (1 equiv) was dissolved in anhydrous dichloromethane (10 mL) with cis-2,6-dimethylmorpholine (1.2 equiv), O-benzotriazole-tetramethyluronium hexafluorophosphate (1.2 equiv), and triethylamine (3 equiv). The mixture was reacted at room temperature for 3 h. After the reaction was confirmed to be complete, the solvent was removed by distillation under reduced pressure, dissolved in ethyl acetate, washed with saturated sodium bicarbonate, 1N dilute hydrochloric acid, and saturated brine in sequence, and purified by column chromatography to obtain intermediate 5a. Under nitrogen protection and ice bath conditions, 5a (1.0 equiv) was dissolved in anhydrous dichloromethane (10 mL), and 17% boron tribromide dichloromethane solution was slowly added dropwise. After the addition was complete, the ice bath was removed and the mixture was reacted at room temperature for 3 h. After the reaction was completed, a saturated ammonium chloride solution was added to quench the reaction, the solvent was removed by distillation under reduced pressure, and the mixture was extracted with ethyl acetate (20 mL×3). Compound 1 was obtained by purification by column chromatography. The synthesis method of compounds 2-26 was similar.

[0082] Synthesis route 2:

[0083]

[0084]

[0085] Reagents and conditions: (a) sodium acetate, sodium acetate borohydride, 1,2-dichloroethane, room temperature, overnight; (b) 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, dichloromethane, room temperature, overnight; (c) boron tribromide, dichloromethane, 0°C, overnight.

[0086] p-Tolualdehyde (1 equiv) and isopropylamine (3 equiv) were dissolved in 1,2-dichloroethane (10 mL), sodium acetate (2 equiv) was added, and the mixture was reacted at room temperature for 3 h. Sodium acetate borohydride (3 equiv) was added three times, and the mixture was reacted at room temperature overnight under nitrogen protection. After the reaction was complete by thin layer chromatography, a saturated sodium bicarbonate solution was added to quench the reaction, the solvent was evaporated under reduced pressure, and the mixture was extracted with ethyl acetate (20 mL×3), and dried over anhydrous sodium sulfate to obtain intermediate 1b. Intermediate 4a (1 equiv) and 1b (1.2 equiv), HBTU (1.2 equiv), and triethylamine (3 equiv) were dissolved in anhydrous dichloromethane (10 mL), and the mixture was reacted at room temperature for 3 h. After the reaction was confirmed to be complete, the solvent was evaporated under reduced pressure, the mixture was dissolved with ethyl acetate, and the mixture was washed with saturated sodium bicarbonate, 1N dilute hydrochloric acid, and saturated brine in sequence, and purified by column chromatography to obtain intermediate 2b. Under nitrogen protection and ice bath conditions, 5a (1.0 equiv) was dissolved in anhydrous dichloromethane (10 mL), and 17% dichloromethane solution of boron tribromide was slowly added dropwise. After the addition was complete, the ice bath was removed and the reaction was allowed to proceed at room temperature for 3 h. After the reaction was completed, saturated ammonium chloride solution was added to quench the reaction, the solvent was evaporated under reduced pressure, and the mixture was extracted with ethyl acetate (20 mL×3). Compound 27 was purified by column chromatography. The preparation methods of compounds 28-42 were similar to those described above.

[0087] Example 1 Synthesis and identification of compounds

[0088] (2-(3,5-difluoro-4-hydroxyphenyl)-4-methylthiazol-5-yl)((2R,6S)-2,6-dimethylmorpholinyl)methanone (1)

[0089]

[0090] 3,5-Difluoro-4-methoxybenzoic acid (1.0 equiv) was dissolved in anhydrous dichloromethane (10 mL), oxalyl chloride (3 equiv) was slowly added dropwise, and then 2-3 drops of N,N-dimethylamide (0.1 equiv) were added dropwise to catalyze. The reaction was carried out at room temperature for 3 hours. After the plate was plated and the reaction was confirmed to be complete, the solvent was distilled off under reduced pressure, dichloromethane was added, and distillation was carried out under reduced pressure. The operation was repeated for more than 3 times to completely remove the residual oxalyl chloride as much as possible, and the chlorinated crude product was obtained for use. Under ice bath conditions, the dichloromethane solution of the above crude product was added dropwise to ammonia water (10 ml). After the addition was completed, the ice bath was removed and the reaction was carried out at room temperature for 1 hour. After the reaction was completed, the solvent was evaporated under reduced pressure, water (10 mL) was added to dilute, the pH was adjusted to be weakly alkaline, and extracted with ethyl acetate (20 mL×3). The organic phases were combined and washed with saturated brine (20 mL×3), and dried over anhydrous sodium sulfate to obtain 1a. 1a (1 equiv) was dissolved in anhydrous tetrahydrofuran, and Lawesson's reagent (1.1 equiv) was added to react at 70°C overnight. After the reaction was complete as determined by thin layer chromatography, a saturated sodium bicarbonate solution was added to quench the reaction, the solvent was evaporated under reduced pressure, water (10 mL) was added to dilute, the pH was adjusted to be weakly alkaline, and ethyl acetate (20 mL×3) was used for extraction. 2a was purified by column chromatography. 2a (1 equiv) and ethyl 2-chloroacetoacetate (6 equiv) were dissolved in anhydrous ethanol, and reacted at 70°C overnight. After the reaction was complete as determined by thin layer chromatography, the temperature was lowered to stand to precipitate crystals, and intermediate 3a was obtained by suction filtration. 3a (1 equiv) was dissolved in a mixed solvent (10 mL) of tetrahydrofuran / methanol / water (3:3:1), and lithium hydroxide monohydrate (1.5 equiv) was added to react at room temperature for 4 h. The solvent was dried by spin drying, and dilute hydrochloric acid was added dropwise to adjust the pH to 3-4 to precipitate a white solid, which was suction filtered and dried to obtain intermediate 4a. 4a (1 equiv) was dissolved in anhydrous dichloromethane (10 mL) with cis-2,6-dimethylmorpholine (1.2 equiv), O-benzotriazole-tetramethyluronium hexafluorophosphate (1.2 equiv), and triethylamine (3 equiv). The reaction was carried out at room temperature for 3 h. After the reaction was confirmed to be complete, the solvent was distilled off under reduced pressure, dissolved in ethyl acetate, washed with saturated sodium bicarbonate, 1N dilute hydrochloric acid and saturated brine in sequence, and purified by column chromatography to obtain intermediate 5a. Under nitrogen protection and ice bath conditions, 5a (1.0 equiv) was dissolved in anhydrous dichloromethane (10 mL), and 17% boron tribromide dichloromethane solution was slowly added dropwise. After the addition was completed, the ice bath was removed and the reaction was carried out at room temperature for 3 h. After the reaction was completed, saturated ammonium chloride solution was added to quench the reaction, the solvent was evaporated under reduced pressure, extracted with ethyl acetate (20 mL×3), and purified by column chromatography to obtain the target compound. Yield: 60%, white powder. 1H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 7.60 (s, 1H), 7.58 (s, 1H), 3.57-3.49 (m, 2H), 2.68 (s, 4H), 2.36 (s, 3H), 1.09 (d, J=5.4Hz, 6H).TOF-MS m / z: calcd for:C 17 H 17 F2N2O3S - [MH] - :367.0933, found:367.0930.

[0091] (2-(3,5-dichloro-4-hydroxyphenyl)-4-methylthiazol-5-yl)((2R,6S)-2,6-dimethylmorpholinyl)methanone (2)

[0092]

[0093] The synthesis method is the same as compound 1. Yield: 68%, white powder. 1 H NMR (400MHz, DMSO-d6) δ7.92-7.80 (m, 2H), 4.37-3.68 (m, 2H), 3.57-3.50 (m, 2H), 2.88-2.54 (m, 2H), 2.37 (s, 3H), 1.09 (d, J=5.5Hz, 6H).TOF-MS m / z:calcd for:C 17 H 17 Cl2N2O3S - [MH] - :399.0342, found:399.0349.

[0094] ((2R,6S)-2,6-dimethylmorpholinyl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (3)

[0095]

[0096] The synthesis method is the same as compound 1. Yield: 70%, white powder. 1 H NMR (500MHz, DMSO-d6) δ11.42 (s, 1H), 7.64-7.44 (m, 1H), 3.60-3.49 (m, 2H), 3.33-3.40 (4H, overlapping with waterpeak), 2.40 (s, 3H), 1.09 (s, 6H). TOF-MS m / z: calcd for: C17 H 18 F3N2O3S + [M+H] + :387.0985, found:387.0981.

[0097] (4-Methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(morpholinyl)methanone (4)

[0098]

[0099] The synthesis method is the same as compound 1. Yield: 78%, white powder. 1H NMR (500MHz, DMSO-d6) δ 11.40 (s, 1H), 7.61-7.47 (m, 1H), 3.62 (s, 4H), 3.53 (s, 4H), 2.42 (s, 3H). TOF-MS m / z: calculation for: C 1s H 14 F3N203S + [M+H] + :359.0672, found:359.0677.

[0100] (4-Hydroxypiperidin-1-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (5)

[0101]

[0102] The synthesis method is the same as compound 1. Yield: 68%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.37 (s, 1H), 7.62-7.42 (m, 1H), 4.82 (s, 1H), 4.08-3.48 (m, 3H), 3.25 (t, J=9.8Hz, 2H), 2.40 (s, 3H), 1.85-1.67 (m, 2H), 1.45-1.28 (m, 2H).TOF-MS m / z:calcd for:C 16 H 14 F3N2O3S - [MH] - :371.0683, found:371.0677.

[0103] (8-Oxo-3-azabicyclo[3.2.1]oct-3-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (6)

[0104]

[0105] The synthesis method is the same as compound 1. Yield: 59%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.38 (s, 1H), 7.60-7.49 (m, 1H), 4.38-4.26 (m, 2H), 3.85-3.5 8(m, 2H), 3.37-3.11(m, 2H), 2.40(s, 3H), 1.87-1.78(m, 2H), 1.70-1.58(m, 2H).TOF-MS m / z:calcd for:C 17 H 14 F3N2O3S - [MH] - :383.0683, found:383.0680.

[0106] ((1R, 3r, 5S)-3-Hydroxy 8-azabicyclo[3.2.1]octan-8-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (7)

[0107]

[0108] The synthesis method is the same as compound 1. Yield: 54%, white powder. 1 H NMR (400MHz, DMSO-d6) δ7.54-7.35 (m, 1H), 4.83-4.15 (m, 2H), 4.08-3.97 (m, 1H), 3.96 (s, 1H), 2.42 (s, 3H), 2.24 (d, J = 7.7Hz, 2H), 2.09-1.83 (m, 4H), 1.74 (d, J = 13.6Hz, 2H).

[0109] TOF-MS m / z:calcd for:C 18 H 16 F3N2O3S - [MH] - :397.0839, found:397.0833.

[0110] (4-Methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(4-methylpiperazin-1-yl)methanone (8)

[0111]

[0112] The synthesis method is the same as compound 1. Yield: 74%, white powder. 1 H NMR (400MHz, DMSO-d6) δ7.60-7.51 (m, 1H), 3.86-3.64 (m, 4H), 3.30-3.21 (m, 4H), 2.82 (s, 3H), 2.44 (s, 3H).TOF-MS m / z: calcd for: C 16 H 15 F3N3O2S - [MH] - :370.0843, found:370.0839.

[0113] 1-(4-(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carbonyl)piperazin-1-yl)ethan-1-one (9)

[0114]

[0115] 4a (1 equiv) was dissolved in anhydrous dichloromethane (10 mL) with 1-boc-piperazine (1.2 equiv), O-benzotriazole-tetramethyluronium hexafluorophosphate (1.2 equiv) and triethylamine (3 equiv). The mixture was reacted at room temperature for 3 h. After the reaction was confirmed to be complete, the solvent was distilled off under reduced pressure and the mixture was dissolved in ethyl acetate. The mixture was washed with saturated sodium bicarbonate, 1N dilute hydrochloric acid and saturated brine in sequence. After drying over anhydrous sodium sulfate, the intermediate was dissolved in dichloromethane (10 ml). Trifluoroacetic acid (3 equiv) was added dropwise under ice bath conditions. The mixture was reacted at room temperature for 2 h. After the reaction was confirmed to be complete, the mixture was adjusted to alkalinity with saturated sodium bicarbonate and filtered to obtain the intermediate without the protecting group. The product (1 equiv) and pyridine (3 equiv) were dissolved in dichloromethane (10 mL), and acetyl chloride (1.2 equiv) was added dropwise under ice bath conditions. After the reaction was confirmed to be complete, the solvent was removed by distillation under reduced pressure, and the mixture was washed with saturated sodium bicarbonate, 1N dilute hydrochloric acid and saturated brine in sequence, and dried over anhydrous sodium sulfate to obtain the intermediate. Under nitrogen protection and ice bath conditions, the above intermediate (1.0 equiv) was dissolved in anhydrous dichloromethane (10 mL), and 17% boron tribromide dichloromethane solution was slowly added dropwise. After the addition was completed, the ice bath was removed and the reaction was allowed to react at room temperature for 3 h. After the reaction was completed, saturated ammonium chloride solution was added to quench the reaction, the solvent was removed under reduced pressure, and the mixture was extracted with ethyl acetate (20 mL×3). The target compound was purified by column chromatography. Yield: 76%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.40 (s, 1H), 7.63-7.48 (m, 1H), 3.61-3.54 (m, 2H), 3.53-3.45 (m, 6H), 2.42 (s, 3H), 2.02 (s, 3H).TOF-MS m / z: calcd for: C 17 H 15 F3N3O3S - [MH] - :398.0792, found:398.0788.

[0116] 1-(4-Methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carbonyl)piperidine-4-carboxylic acid methyl ester (10)

[0117]

[0118] The synthesis method is the same as compound 1. Yield: 64%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.37 (s, 1H), 7.62-7.38 (m, 1H), 3.62 (s, 3H), 3.36 (s, 2H), 3.12 ( s, 2H), 2.74-2.63 (m, 1H), 2.40 (s, 3H), 1.90 (d, J=11.6Hz, 2H), 1.60-1.46 (m, 2H).TOF-MS m / z:calcd for:C 18 H 16 F3N2O4S - [MH] - :413.0788, found:413.0785.

[0119] Isoindolin-2-yl(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone(11)

[0120]

[0121] The synthesis method is the same as compound 1. Yield: 68%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.39 (s, 1H), 7.63-7.53 (m, 1H), 7.43-7.36 (m, 1H), 7.33-7.27 (m, 3H), 4.87 (s, 2H), 4.84 (s, 2H), 2.52 (s, 3H).TOF-MS m / z:calcd for:C 19 H12 F3N2O2S - [MH] - :389.0577, found:389.0578.

[0122] (3,4-Dihydroisoquinolin-2(1H)-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone (12)

[0123]

[0124] The synthesis method is the same as compound 1. Yield: 71%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.38 (s, 1H), 7.62-7.52 (m, 1H), 7.19 (s, 4H), 4.82-4.65 (m, 2H), 3.87-3.65 (m, 2H), 2.94-2.82 (m, 2H), 2.42 (s, 3H).TOF-MS m / z:calcd for:C 20 H 14 F3N2O2S - [MH] - :403.0734, found:403.0728.

[0125] (4-Methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(4-phenylpiperidin-1-yl)methanone (13)

[0126]

[0127] The synthesis method is the same as compound 1. Yield: 53%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.39 (s, 1H), 7.57-7.50 (m, 1H), 7.32-7.29 (m, 1H), 7.29-7.24 (m, 3H), 7.22-7.17 (m, 1H), 4.74-3.55 (m, 2 H), 3.22-2.95 (m, 2H), 2.82 (t, J=12.0Hz, 1H), 2.44 (s, 3H), 1.83 (d, J=12.1Hz, 2H), 1.63 (d, J=11.7Hz, 1H), 1.58 (d, J=11.7Hz, 1H).

[0128] TOF-MS m / z:calcd for:C 22 H 18 F3N2O2S -[MH] - :431.1047, found:431.1035.

[0129] 4-Methyl-N-(p-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (14)

[0130] The synthesis method is the same as compound 1. Yield: 50%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.42 (s, 1H), 10-20 (s, 1H), 7.63-7.57 (m, 1H), 7.56 (d, J=8.4Hz, 2H), 7.15 (d, J=8.3Hz, 2H), 2.65 (s, 3H), 2.27 (s, 3H).TOF-MS m / z:calcd for:C 18 H 12 F3N2O2S - [MH] - :377.0577, found:377.0573.

[0131] 4-Methyl-N-(m-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (15)

[0132]

[0133] The synthesis method is the same as compound 1. Yield: 50%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.43 (s, 1H), 10.21 (s, 1H), 7.62-7.55 (m, 1H), 7.52 (s, 1H), 7.47 (d, J=8.2Hz, 1H), 7.23 (t, J=7.8Hz, 1H), 6.94 (d, J=7.5Hz, 1H), 2.65 (s, 3H), 2.30 (s, 3H).TOF-MS m / z:calcd for:C 18 H 12 F3N2O2S - [MH] - :377.0577, found:377.0571.

[0134] N-(2-Chlorophenyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (16)

[0135]

[0136] The synthesis method is the same as compound 1. Yield: 51%, white powder. 1 H NMR (400MHz, DMSO-d6) δ10.02 (s, 1H), 7.64 (d, J=6.6Hz, 1H), 7.63-7.58 (m, 1H), 7.5 6(d, J=6.6Hz, 1H), 7.39 (t, J=8.4Hz, 1H), 7.31 (t, J=8.5Hz, 1H), 2.72 (s, 3H).TOF-MS m / z:calcd for:C 17 H9ClF3N2O2S - [MH] - :397.0031, found:397.0027.

[0137] N-Benzyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (17)

[0138]

[0139] The synthesis method is the same as compound 1. Yield: 71%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.41 (s, 1H), 8.90 (t, J=5.5Hz, 1H), 7.61-7.47 (m, 1H), 7-41-7.28(m, 4H), 7.29-7.22(m, 1H), 4-44(d, J=5.7Hz, 2H), 2.63(s, 3H).TOF-MS m / z:calcd for:C 18 H 12 F3N2O2S - [MH] - :377.0577, found:377.0573.

[0140] N-(4-Chlorobenzyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (18)

[0141]

[0142] The synthesis method is the same as compound 1. Yield: 66%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.40 (s, 1H), 8.91 (t, J=5.9Hz, 1H), 7.60-7.51 (m, 1H), 7.4 0 (d, J=8.6Hz, 2H), 7.35 (d, J=8.5Hz, 2H), 4.42 (d, J=5.9Hz, 2H), 2.63 (s, 3H).TOF-MS m / z:calcd for:C 18 H 11 ClF3N2O2S - [MH] - :411.0187, found:411.0182.

[0143] 4-Methyl-N-(1-phenylethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (19)

[0144]

[0145] The synthesis method is the same as compound 1. Yield: 68%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.43 (s, 1H), 8.80 (d, J = 7.9Hz, 1H), 7.63-7.48 (m, 1H), 7.39 (d, J = 7.3Hz, 2H), 7. 34 (t, J=7.6Hz, 2H), 7.24 (t, J=7.2Hz, 1H), 5.21-5.04 (m, 1H), 2.59 (s, 3H), 1.47 (d, J=7.0Hz, 3H).TOF-MS m / z:calcd for:C 19 H 14 F3N2O2S - [MH] - :391.0734, found:391.0724.

[0146] N-(Cyclopropyl(phenyl)methyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (20)

[0147]

[0148] The synthesis method is the same as compound 1. Yield: 55%. White powder. 1H NMR (400MHz, DMSO-d6) δ11.42 (s, 1H), 9.10 (s, 1H), 7.61-7.53 (m, 1H), 7.29 (t, J=7.6Hz, 2H), 7.21 (d, J= 7.3Hz, 2H), 7.17 (t, J=7.2Hz, 1H), 4.05 (s, 1H), 2.61 (s, 3H), 2.06 (s, 1H), 1.27 (d, J=10.1Hz, 4H).TOF-MS m / z:calcd for:C 21 H 16 F3N2O2S - [MH] - :417.0890, found:417.0883.

[0149] N-Benzyl-N,4-dimethyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (21)

[0150]

[0151] The synthesis method is the same as compound 1. Yield: 68%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.39 (s, 1H), 7.56-7.50 (m, 1H), 7.40-7.36 (m, 2H), 7.34-7.19 (m, 3H), 4.65 (s, 2H), 2.92 (s, 3H), 2.41 (s, 3H).TOF-MS m / z:calcd for:C 19 H 14 F3N2O2S - [MH] - :391.0734, found:391.0726.

[0152] N-Benzyl-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (22)

[0153]

[0154] The synthesis method is the same as compound 1. Yield: 69%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.35 (s, 1H), 7.58-7.44 (m, 1H), 7.37-7.31 (m, 2H), 7.31-7.25 (m, 2H) , 7.25-7.20 (m, 1H), 4.62 (s, 2H), 4.38-4.06 (m, 1H), 2.42 (s, 3H), 1.13 (d, J=6.5Hz, 6H).TOF-MS m / z:calcd for:C 21 H 18 F3N2O2S - [MH] - :419.1047, found:419.1044.

[0155] N-Benzyl-N-cyclopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (23)

[0156]

[0157] The synthesis method is the same as compound 1. Yield: 68%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.39 (s, 1H), 7.60-7.52 (m, 1H), 7.40-7.35 (m, 2H), 7.32-7.27 (m, 3H), 4.68 (s, 2H), 2.69-2.63 (m, 1H), 2.43 (s, 3H), 0.64 (s, 2H), 0.63 (s, 2H).TOF-MS m / z:calcd for:C 21 H 16 F3N2O2S - [MH] - :417.0890, found:417.0880.

[0158] N-Benzyl-4-methyl-N-phenyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (24)

[0159]

[0160] The synthesis method is the same as compound 1. Yield: 38%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.31 (s, 1H), 7.48-7.40 (m, 1H), 7-33-7.31 (m, 1H), 7.30-7.28 (m, 3H), 7.28-7.25 (m, 2H ), 7.25-7.23(m, 1H), 7.24-7.20(m, 1H), 7.19-7.17(m, 1H), 7.17-7.12(m, 1H), 5.10(s, 2H), 2.46(s, 3H).TOF-MS m / z:calcd for:C 24 H 16 F3N2O2S - [MH] - :453.0890, found:453.089.

[0161] N, N-dibenzyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (25)

[0162]

[0163] The synthesis method is the same as compound 1. Yield: 67%, white powder. 1 H NMR (400MHz, DMSo-d6) δ11.37 (s, 1H), 7.55-7.48 (m, 1H), 7.40-7.34 (m, 4H), 7.34-7.26 (m, 3H), 7.27-7.13 (m, 3H), 4.57 (s, 4H), 2.39 (s, 3H).TOF-MS m / z:calcd for:C 25 H 18 F3N2O2S - [MH] - :467.1047, found:467.1042.

[0164] N-Benzyl-4-methyl-N-(1-phenylethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (26)

[0165]

[0166] The synthesis method is the same as compound 1. Yield: 46%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.37 (s, 1H), 7.55-7.48 (m, 1H), 7.42-7.35 (m, 3H), 7.35-7.27 (m, 3H), 7.27-7.21 (m, 2H), 7.19-7.15 ( m, 1H), 7.12-7.05 (m, 1H), 5.83-5.08 (m, 1H), 4.73-4.57 (m, 1H), 4.36-4.06 (m, 1H), 2.42 (s, 3H), 1.54 (d, J=7.0Hz, 3H).TOF-MS m / z:calcd for:C 26 H 20 F3N2O2S - [MH] - :481.1203, found:481.1200.

[0167] N-isopropyl-4-methyl-N-(2-methylbenzyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (27)

[0168]

[0169] 2-Methylbenzaldehyde (1equiv) and isopropylamine (3equiv) were dissolved in 1,2-dichloroethane (10mL), sodium acetate (2equiv) was added, and the mixture was reacted at room temperature for 3h. Sodium acetate borohydride (3equiv) was added three times, and the mixture was reacted at room temperature overnight under nitrogen protection. After the reaction was complete by thin layer chromatography, a saturated sodium bicarbonate solution was added to quench the reaction, the solvent was evaporated under reduced pressure, and the mixture was extracted with ethyl acetate (20mL×3), and dried over anhydrous sodium sulfate to obtain intermediate 1b. Intermediate 4a (1equiv) and 1b (1.2equiv), HBTU (1.2equiv), and triethylamine (3equiv) were dissolved in anhydrous dichloromethane (10mL), and the mixture was reacted at room temperature for 3h. The mixture was plated and the reaction was confirmed to be complete. The solvent was evaporated under reduced pressure, and the mixture was dissolved in ethyl acetate. The mixture was washed with saturated sodium bicarbonate, 1N dilute hydrochloric acid, and saturated brine in sequence, and purified by column chromatography to obtain intermediate 2b. Under nitrogen protection and ice bath conditions, 5a (1.0 equiv) was dissolved in anhydrous dichloromethane (10 mL), and 17% dichloromethane solution of boron tribromide was slowly added dropwise. After the addition was completed, the ice bath was removed and the reaction was allowed to proceed at room temperature for 3 h. After the reaction was completed, saturated ammonium chloride solution was added to quench the reaction, the solvent was evaporated under reduced pressure, and the product was extracted with ethyl acetate (20 mL × 3). The target compound was obtained by column chromatography purification. Yield: 51%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.38 (s, 1H), 7.58-7.47 (m, 1H), 7.22-7.17 (m, 1H), 7.17-7.13 (m, 2H), 7.13- 7.09 (m, 1H), 4.53 (s, 2H), 4.39-4.13 (m, 1H), 2.47 (s, 3H), 2.28 (s, 3H), 1.15 (d, J=6.6Hz, 6H).TOF-MS m / z:calcd for:C 22 H 20 F3N2O2S - [MH]-:433.1203.found:433.1181.

[0170] N-isopropyl-4-methyl-N-(4-methylbenzyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (28)

[0171]

[0173] The synthesis method is the same as compound 27. Yield: 65%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.38 (s, 1H), 7.59-7.46 (m, 1H), 7.22-7.14 (m, 2H), 7.14-7.13 (m, 1H), 7.13-7.09 (m, 1H), 4.56 (s, 2H), 4.37-4.00 (m, 1H), 2.41 (s, 3H), 2.26 (s, 3H), 1.12 (d, J=6.5Hz, 6H).TOF-MSm / z: calcd for:C 22 H 20 F3N2O2S - [MH] - :433.1203, found:433.1197.

[0174] N-(4-Fluorobenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (29)

[0175]

[0176] The synthesis method is the same as compound 27. Yield: 76%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.39 (s, 1H), 7.57-7.50 (m, 1H), 7.39-7.28 (m, 2H), 7.20-7. 10 (m, 2H), 4.60 (s, 2H), 4.34-4.07 (m, 1H), 2.41 (s, 3H), 1.13 (d, J=6.2Hz, 6H).TOF-MS m / z:calcd for:C 21 H 17 F4N2O2S - [MH] - :437.0952, found:437.0949.

[0177] N-(4-Chlorobenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-55-carboxamide (30)

[0178]

[0179] The synthesis method is the same as compound 27. Yield: 78%, white powder. 1 H NMR (400MHz, DMSO-d6) δ7.59-7.46 (m, 1H), 7.39 (d, J=8.3Hz, 2H), 7.36-7.20 (m, 2H), 4.60 (s, 2H), 4.31-4.03 (m, 1H), 2.41 (s, 3H), 1.13 (d, J=6.6Hz, 6H).TOF-MS m / z:calcd for:C 21 H 17 ClF3N2O2S - [MH] - :453.0657, found:453.0651.

[0180] N-(3,4-dichlorophenyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (31)

[0181]

[0182] The synthesis method is the same as compound 27. Yield: 51%, white powder. 1H NMR (400MHz, DMSO-d6) δ7.59 (d, J=8.3Hz, 1H), 7.56-7.43 (m, 2H), 7.33-7.24 (m, 1H), 4.60 (s, 2H), 4.25-4.06 (m, 1H), 2.41 (s, 3H), 1.13 (d, J=6.6Hz, 6H).TOF-MS m / z:calcd for:C 21 H 16 Cl2F3N2O2S - [MH] - :487.0267, found:487.0266.

[0183] N-(4-chloro-2-methylbenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (32)

[0184]

[0185] The synthesis method is the same as compound 27. Yield: 55%, white powder. 1 H NMR (400MHz, DMSO-d6) δ7.56-7.49 (m, 1H), 7.27-7.22 (m, 2H), 7.16-7.08 (m, 1H), 4.4 9(s, 2H), 4.34-4.16(m, 1H), 2.45(s, 3H), 2.28(s, 3H), 1.14(d, J=6.6Hz, 6H).TOF-MS m / z:calcd for:C 22 H 19 ClF3N2O2S - [MH] - :467.0813, found:467.0808.

[0186] N-(4-Hydroxy-3,5-dimethylbenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (33)

[0187]

[0188] The synthesis method is the same as compound 27. Yield: 46%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.37 (s, 1H), 8.13 (s, 1H), 7.57-7.49 (m, 1H), 6.79 (s, 2H), 4. 43(s, 2H), 4.32-4.07(m, 1H), 2.41(s, 3H), 2.11(s, 6H), 1.12(d, J=6.2Hz, 6H).TOF-MS m / z:calcd for:C 23 H 22 F3N2O3S - [MH] - :463.1309, found:463.1305.

[0189] N-isopropyl-4-methyl-N-(thiophen-2-ylmethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (34)

[0190]

[0191] The synthesis method is the same as compound 27. Yield: 50%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.38 (s, 1H), 7.59-7.48 (m, 1H), 7.40 (d, J=3.9Hz, 1H), 7.05 (s, 1H), 6.94 (dd, J=5.0, 3.5Hz, 1H), 4.77 (s, 2H), 4.28-3.96 (m, 1H), 2.39 (s, 3H), 1.17 (d, J=6.6Hz, 6H).TOF-MS m / z:calcd for:C 19 H 16 F3N2O2S2 - [MH] - :425.0611, found:425.0606.

[0192] N-isopropyl-4-methyl-N-(thiazol-4-ylmethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (35)

[0193]

[0194] The synthesis method is the same as compound 27. Yield: 58%, white powder. 1H NMR (400MHz, DMSO-d6) δ9.06 (s, 1H), 7.56-7.49 (m, 1H), 7.48 (s, 1H), 4.67 (s, 2H), 4.05-4.01 (m, 1H), 2.39 (s, 3H), 1.14 (d, J=6.7Hz, 6H).TOF-MS m / z:calcd for:C 18 H 15 F3N3O2S2 - [MH] - :426.0563, found:426.0561.

[0195] N-(Benzothiophen-2-ylmethyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (36)

[0196]

[0197] The synthesis method is the same as compound 27. Yield: 68%, white powder. 1 H NMR (400MHz, DMSo-d6) δ11.39 (s, 1H), 7.91 (d, J = 7.5Hz, 1H), 7.77 (d, J = 7.2Hz, 1H), 7.58-7.50 (m, 1H) , 7.39 (s, 1H), 7.36-7.28 (m, 2H), 4.89 (s, 2H), 4.16 (s, 1H), 2.43 (s, 3H), 1.21 (d, J=6.6Hz, 6H).TOF-MS m / z:calcd for:C 23 H 18 F3N2O2S2 - [MH] - :475.0767, found:475.0764.

[0198] N-(Benzofuran-2-ylmethyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (37)

[0199]

[0200] The synthesis method is the same as compound 27. Yield: 65%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.37 (s, 1H), 7.58 (d, J=7.5Hz, 1H), 7.56-7.48 (m, 2H), 7.29-7.24 (m, 1H), 7 .24-7.19 (m, 1H), 6.76 (s, 1H), 4.75 (s, 2H), 4.22 (s, 1H), 2.43 (s, 3H), 1.20 (d, J=6.7Hz, 6H).TOF-MS m / z:calcd for:C 23 H 18 F3N2O3S - [MH] - :459.0996, found:459.0990.

[0201] N-Benzyl-4-methyl-N-(p-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (38)

[0202]

[0203] The synthesis method is the same as compound 27. Yield: 40%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.32 (s, 1H), 7.48-7.39 (m, 1H), 7.33-7.30 (m, 1H), 7.30-7.28 (m, 1H), 7.28-7.27 (m, 1H), 7.26-7 .24 (m, 1H), 7.25-7.21 (m, 1H), 7.08 (d, J=8.3Hz, 2H), 7.03 (d, J=8.4Hz, 2H), 5.06 (s, 2H), 2.45 (s, 3H), 2.20 (s, 3H).TOF-MS m / z:calcd for:C 25 H 18 F3N2O2S - [MH] - :467.1047, found:467.1040.

[0204] N-(4-Chlorobenzyl)-N-isobutyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (39)

[0205]

[0206] The synthesis method is the same as compound 27. Yield: 58%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.38 (s, 1H), 7.57-7.50 (m, 1H), 7.45-7.41 (m, 2H), 7.37-7.05 (m, 2H ), 4.64(s, 2H), 3.24-3.05(m, 2H), 2.38(s, 3H), 2.12-1.92(m, 1H), 0.96-0.64(m, 6H).TOF-MS m / z:calcd for:C 22 H 19 ClF3N2O2S - [MH] - :467.0813, found:467.0810.

[0207] N-(4-Chlorobenzyl)-4-methyl-N-phenethyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (40)

[0208]

[0209] The synthesis method is the same as compound 27. Yield: 67%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.37 (s, 1H), 7.53-7.47 (m, 1H), 7.47-7.34 (m, 3H), 7.36-7.14 (m, 5H), 7.11-6.96 (m, 1 H), 4.90-4.67(m, 1H), 4.66-4.37(m, 1H), 3.67-3.45(m, 2H), 2.96-2.72(m, 2H), 2.27(s, 3H).TOF-MSm / z: calcd for:C26H 19 ClF3N2O2S - [MH] - :515.0813, found:515.0810.

[0210] N-(4-Chlorobenzyl)-4-methyl-N-(4-methylphenethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (41)

[0211]

[0212] The synthesis method is the same as compound 27. Yield: 62%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.37 (s, 1H), 7.53-7.46 (m, 1H), 7.46-7.14 (m, 4H), 7.16-6.84 (m, 4H), 4.85-4.66 ( m, 1H), 4.67-4.25 (m, 1H), 3.68-3.43 (m, 2H), 2.93-2.65 (m, 2H), 2.27 (s, 3H), 2.24 (s, 3H).TOF-MSm / z: calcd for:C 27 H 21 ClF3N2O2S - [MH] - :529.0970, found:529.0964.

[0213] N-(4-Chlorobenzyl)-4-methyl-N-(3-phenylpropyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide (42)

[0214]

[0215] The synthesis method is the same as compound 27. Yield: 60%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.38 (s, 1H), 7.57-7.49 (m, 1H), 7.45-7.42 (m, 1H), 7.41-7.40 (m, 1H), 7.35-7.21 (m, 2H), 7.22-7 .07(m, 3H), 7.08-6.94(m, 2H), 4.66(s, 2H), 3.35-3.09(m, 2H), 2.49-2.37(m, 2H), 2.36(s, 3H), 1.92-1.72(m, 2H).TOF-MS m / z:calcd for:C 27 H 21 ClF3N2O2S - [MH] - :529.0970, found:529.0966.

[0216] Example 2 HSD17B13 inhibitory activity test

[0217] The compound was prepared into different concentrations of 10% DMSO solution with 25 mM Tris solution (containing 0.02% Triton X-100), 0.4 μL was added to a 384-well white plate, and then 2 μL of HSD17B13 protein (120 nM, final concentration) was added and mixed, and finally 2 μL of 75 μM β-estradiol (0.05% DMSO) and 500 μM NAD were added.+ Mix the substrates, place on a shaker at 25°C, incubate for 2 hours in the dark, and then add 3 μL of NAD(P)H-Glo TM The detection reagent was added and incubated again for 1 hour. The luminescence value was measured using a Thermo multifunctional microplate reader. The reported HSD17B13 inhibitor BI-3231 was used as a positive control. The test results are shown in Table 1.

[0218] Table 1: HSD17B13 inhibitory activity

[0219]

[0220] Note: IC 50 Values ​​are the average of three independent experiments

[0221] The above results show that the compounds of the present invention have good HSD17B13 inhibitory activity.

[0222] Example 3 Distribution Study of Preferred Compound 30

[0223] Five-week-old male C57BL / 6 mice weighing 16-17g were purchased from Guangdong Medical Experimental Animal Center (License No.: SCXK(Y)2022-0002) and raised in an SPF barrier environment. During the entire experiment, the temperature and relative humidity of the animal room were controlled at 23±2°C, 50±10%, and the light / dark cycle was constant at 12 hours. Before starting the animal experiment, all mice were adaptively raised for one week. Unless otherwise stated, mice were raised under specific pathogen-free conditions with free access to feed and water. The mice were randomly divided into 7 groups (1, 4, 8, 12, 24, 36, 72h, seven time points), 3 mice in each group. Fasting for 8h before gavage (free drinking water), a single dose of compound 30 (20mg / kg, solvent is 0.5% CMC-Na). Before sampling, mice were anesthetized by intraperitoneal injection of 2% sodium pentobarbital (50 mg / kg), and then blood was collected by orbital sampling. Mice were killed by cervical dislocation and fixed on a mouse stand. The skin, subcutaneous tissue, and peritoneum were cut along the midline of the abdomen to expose the abdominal cavity. The liver tissue was removed, washed with saline, and one-third of the liver lobe was uniformly cut for subsequent ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometry detection. The experimental results are shown in the attached Figure 1 .

[0224] The experimental results showed that after oral administration, the content of compound 30 in mouse serum was low and could not be detected after 24 hours. The drug content in the liver was 50 times that in serum, and 2000nmmol / L of compound 30 could still be detected in the mouse liver after 72 hours (the half enzyme inhibition activity in vitro was 2.46±0.93nM). The results showed that compound 30 had a persistent liver-targeted distribution characteristic and could exert a persistent therapeutic effect on the liver target organ (Appendix Figure 1).

[0225] Example 4: Effects of Preferred Compound 30 on Hypoglycemic and Lipid-Regulating Effects in DIO Mice

[0226] The mice were randomly divided into a normal group, a model group, an obeticholic acid (OCA) administration group, and a test compound administration group, with 6 mice in each group. The normal group was given normal basal feed and drinking water, and the other groups were fed with a high-fat diet (Dyets, HF60, 60 kcal% fat calories). The model was continuously established for 20 weeks to induce the DIO model. Starting from the 21st week, daily gavage was performed, and the normal group and the model group were given 0.5% sodium carboxymethylcellulose (CMC-Na), OCA group (20 mg / kg), and compound 30 group (20 mg / kg) for 4 weeks. Fasting for 8 hours before sampling (free drinking water), 2% sodium pentobarbital (50 mg / kg) was given for intraperitoneal anesthesia, and then blood was collected through orbital bleeding. The mice were killed by cervical dislocation, fixed on a mouse platform, and the skin, subcutaneous tissue, and peritoneum were cut along the midline of the abdomen in turn to expose the abdominal cavity, and the liver tissue was removed. After washing with physiological saline, the liver tissue of the left lobe of appropriate size was uniformly cut and soaked in tissue fixative for fixation. (Take 1×1×0.5cm at 5mm from the edge of the right lobe of the liver 3 The liver tissues were fixed in 4% paraformaldehyde for paraffin embedding and HE staining. The remaining tissues were placed in cryopreservation tubes sealed with liquid nitrogen and stored in a -80℃ refrigerator for later use. Figure 2 and 3 .

[0227] The experimental results showed that the blood glucose level in the model group increased rapidly and significantly, indicating impaired glucose tolerance. The compound 30 treatment group significantly improved the oral glucose tolerance of DIO mice. Compared with the model group, the blood glucose area under the curve (AUC 0-90min Compared with the normal group, there was no significant difference in the serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), bile acid (TBA), alkaline phosphatase (ALP) and uric acid (UA) levels of mice in the compound 30 treatment group, indicating that compound 30 has good safety at the effective dose (Appendix Figure 2 ).

[0228] HE pathological sections observed diffuse hepatic fatty degeneration in the model group. Compared with the model group, the lipid vacuoles in the treatment group were significantly reduced, and the results of MAFLD activity score (NAS) showed that the therapeutic effect of compound 30 was comparable to that of OCA. In addition, compared with the normal group, the levels of total triglyceride (TG) and total cholesterol (TC) in the liver and serum TC and low-density lipoprotein (LDL) in the DIO mouse model induced by a high-fat diet were significantly increased, and the levels of inflammatory factors in the liver of the model group were also significantly increased. The serum lipid changes in the compound 30-treated group were improved, and the levels of liver inflammatory factors, including interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and activated monocyte chemoattractant protein 1 (MCP-1) were significantly reduced, and the effect was comparable to that of OCA (Appendix Figure 3 ).

[0229] Example 5 In vivo anti-MASH activity study

[0230] Mice were randomly divided into a normal group, a model group, an obeticholic acid (OCA) administration group, and a compound 30 group, with 6 mice in each group. The normal group was given normal basal feed and drinking water, and the other groups were fed a high-fat diet (Dyets, D18061501, containing 21.1% fat, 41% fructose, and 1.25% cholesterol) and prepared with sugar water (23.1 g / L fructose: 18.9 g / L glucose). At the same time, except for the normal group, the other groups were intraperitoneally injected with 0.3 μL / g CCl4 oil solution once a week, and the model was continuously built for 12 weeks to induce the NASH model. Starting from the 9th week, daily gavage was performed, and the normal group and the model group were given 0.5% sodium carboxymethyl cellulose (CMC-Na), OCA group (20 mg / kg), and the test compound group (20 mg / kg) for 4 weeks. Half an hour after the last administration, 0.3 μL / g CCl4 oil solution was injected. The mice were fasted for 8 hours before sampling (free drinking water), and 2% sodium pentobarbital (50 mg / kg) was given for intraperitoneal anesthesia. Blood was then collected by orbital bleeding. The mice were killed by cervical dislocation and fixed on a mouse stand. The skin, subcutaneous tissue, and peritoneum were cut along the midline of the abdomen to expose the abdominal cavity. The liver tissue was removed, washed with physiological saline, and the liver tissue of the left lobe of appropriate size was uniformly cut and soaked in tissue fixative for fixation. (1×1×0.5cm was taken from the right lobe of the liver 5mm away from the edge. 3 The large and small liver tissues were fixed in 4% paraformaldehyde for paraffin embedding and HE and Masson staining. The remaining tissues were placed in cryopreservation tubes, sealed with liquid nitrogen, and then stored in a -80℃ refrigerator for later use. The experimental results are attached. Figure 4 .

[0231] The experimental results showed that the HE pathological sections showed that the model induced the typical histological characteristics of fatty liver hepatitis, including fatty degeneration, lobular inflammation and ballooning of hepatocytes. Compared with the model group, the treatment group had significantly fewer lipid vacuoles, significantly reduced inflammation, normal hepatocyte morphology, no ballooning, and neatly arranged cells. The MAFLD activity score (NAS) results showed that the therapeutic effect of compound 30 was comparable to that of OCA. The collagen fibers in the Masson pathological sections appeared blue under a white light microscope, and more than half of the blue area showed that the collagen fiber deposition in the liver of this model was severe. Compared with the model group, the blue-stained area of ​​collagen in the treatment group was mainly distributed around the central vein and the portal area, and the collagen deposition in the liver tissue was reduced. Quantitative analysis of Masson staining showed that the anti-fibrosis results of compound 30 were comparable to those of OCA (Appendix Figure 4 ), indicating that the compounds of the present invention have good anti-fatty hepatitis efficacy and have broad development prospects comparable to the drugs under clinical research.

Claims

1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: in, R1 is selected from any of the following structures: R2 is selected from any of the following structures: Wherein, R3 is selected from one or more hydrogen, halogen, alkyl, hydroxyl, alkoxy, R4 and R5 are each independently selected from hydrogen, alkyl, cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl is optionally further substituted by one or more groups selected from halogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl.

2. A compound of the general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof: R1 is selected from any of the following structures: R2 is selected from any of the following structures: in, R3 is selected from one or more of hydrogen, halogen, C1-C 10 alkyl, hydroxyl, C1-C6 alkoxy, R4 and R5 are each independently selected from hydrogen, C1-C 10 Alkyl, C3-C6 cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl, aryl, heteroaryl.

3. The compound of general formula (I) as defined in any one of claims 1 to 2 is selected from: (2-(3,5-dichloro-4-hydroxyphenyl)-4-methylthiazol-5-yl)((2R,6S)-2,6-dimethylmorpholinyl)methanone; (2-(3,5-difluoro-4-hydroxyphenyl)-4-methylthiazol-5-yl)((2R,6S)-2,6-dimethylmorpholinyl)methanone; (4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(morpholinyl)methanone; (4-Hydroxypiperidin-1-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone; ((2R,6S)-2,6-dimethylmorpholinyl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone; (8-Oxo-3-azabicyclo[3.2.1]octan-3-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone; ((1R,3R,5S)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone; (4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(4-methylpiperazin-1-yl)methanone; 1-(4-(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carbonyl)piperazin-1-yl)ethan-1-one; 1-(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carbonyl)piperidine-4-carboxylic acid methyl ester; Isoindolin-2-yl(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone; (3,4-dihydroisoquinolin-2(1H)-yl)(4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)methanone; (4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazol-5-yl)(4-phenylpiperidin-1-yl)methanone; 4-methyl-N-(p-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; 4-Methyl-N-(m-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(2-chlorophenyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-Benzyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-Benzyl-N,4-dimethyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-Benzyl-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-Benzyl-N-cyclopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-Benzyl-4-methyl-N-phenyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-Benzyl-4-methyl-N-(p-tolyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N, N-dibenzyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-Benzyl-4-methyl-N-(1-phenylethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; 4-Methyl-N-(1-phenylethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(Cyclopropyl(phenyl)methyl)-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-isopropyl-4-methyl-N-(2-methylbenzyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-isopropyl-4-methyl-N-(4-methylbenzyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-Fluorobenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-Hydroxy-3,5-dimethylbenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-isopropyl-4-methyl-N-(thiophen-2-ylmethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(Benzothiophen-2-ylmethyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(Benzofuran-2-ylmethyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(3,4-dichlorophenyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chloro-2-methylbenzyl)-N-isopropyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-N-isobutyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-4-methyl-N-(4-methylphenethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-4-methyl-N-phenethyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-4-methyl-N-(3-phenylpropyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-N-isobutyl-4-methyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-4-methyl-N-phenethyl-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-(4-chlorobenzyl)-4-methyl-N-(4-methylphenethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide; N-isopropyl-4-methyl-N-(thiazol-4-ylmethyl)-2-(2,4,5-trifluoro-3-hydroxyphenyl)thiazole-5-carboxamide.

4. A pharmaceutical composition comprising the compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof and a suitable carrier or excipient.

5. Use of a compound as defined in any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating HSD17B13-mediated diseases.

6. Use of a compound as defined in any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined in claim 4, in the preparation of a medicament for preventing and / or treating at least one of primary biliary cirrhosis, nonalcoholic steatohepatitis, alcoholic steatohepatitis, hyperlipidemia, obesity, atherosclerosis, organ fibrosis, cirrhosis, diabetes and its complications, acute kidney injury, and inflammatory diseases.

Citation Information

Cited By

  • Hydroxypyridine HSD17B13 inhibitors and uses thereof

    US12617772B2

  • Thiophene HSD17B13 inhibitors and uses thereof

    US12673930B2

  • Thiazole HSD17B13 inhibitors and uses thereof

    US12774278B2